Significant epidemiological changes in chronic hepatitis C infection: Results of the nationwide HEPNET-GREECE cohort study

Hippokratia

Volumn 15, Issue 1, 2011, Pages 26-31

  Raptopoulou, M ^a   Touloumi, G ^b   Tzourmakliotis, D ^c   Nikolopoulou, G ^d   Dimopoulou, M ^e   Giannoulis, G ^f   Vasiliadis, T ^a   Skoutelis, A ^g   Anagnostou, O ^b   Hatzis, G ^b   Manolakopoulos, S ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d HCDCP (KEELPNO)   (Greece)

^e HIPPOKRATION HOSPITAL   (Greece)

^f TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^g EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Greece; Hcv genotypes; Hepatitis c epidemiology; Intravenous drug use; Transfusion

Indexed keywords

ADULT; ANAMNESIS; ARTICLE; BLOOD TRANSFUSION; COHORT ANALYSIS; DISEASE TRANSMISSION; DRUG ABUSE; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; GENOTYPE; GREECE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE;

EID: 79251531659     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hoofnagle JH, DiBisceleglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 1997; 336: 347-356.
2. Lavanchy D. The global burden of hepatitis. C. Liver Int, 2009; 29 (Suppl 1): 74-81.
3. Gogos CA, Fouka KP, Nikiforidis G, Avgeridis K, Sakellaro- poulos G, Bassaris H, et al. Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol. 2003; 18: 551-557.
4. Goritsas C, Plerou I, Agaliotis S, Spinthaki R, Mimidis K, Velissaris D, et al. HCV infection in the general population of a Greek island: prevalence and risk factors. Hepatogastroenterology. 2000; 47: 782-785.
5. Koulentaki M, Spanoudakis S, Kantidaki E, Drankakis P, Tzagarakis N, Biziagos E, et al. Prevalence of hepatitis B and C markers in volonteer blood donors in Crete. A 5-year study. J Viral Hepat. 1999; 6: 243-248.
6. M. Malliori, V. Sypsa, M. Psichogiou, Touloumi, A. Skoutelis, N. Tassopoulos, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction. 1998; 93: 243-251.
7. Sypsa V, Touloumi G, Papatheodoridis GV, Tassopoulos NC, Ketikoglou I, Vafiadis I, et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently avail-able treatments. J Viral Hepat. 2005; 12: 543-550.
8. Bourliene M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecompte L, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J Viral Hepat. 2002; 9: 62-70.
9. Dal Molin G, Ansaldi F, Biagi C, D'Agano P, Comar M, Croc L, et al. Changing molecular epidemiology of hepatitis C virus infection in northeast Italy. J Med Virol. 2002; 68: 352-356.
10. Savvas SP, Koskinas J, Sinani C, Hadziyannis A, Spanou F, Hadziyannis SJ. Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat. 2005; 12: 551-557.
11. Harris KA, Gilham V, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol. 1999; 58: 127-131.
12. Eldin BR, Carden MR. Injection drug users: the overlloked core of the hepatitis C epidemic. Clin Infect Dis. 2006; 42: 673-676.
13. Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafouli- dou A, Ketikoglou I, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV-specific incidence and in molecular characterization of genotype 4 isolates. J Viral Hepat. 2006; 13: 19-27.
14. Lyra AC, Ramrakhiani S, Bacon RR, DiBiscelie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol. 2004; 38: 68-71.
15. Tamalet C, Colson P, Tissot-Dupont H, Henry M, Tourres Ch, Tivolo N, et al. Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol. 2003; 71: 391-398.